By Gina Shaw
Mylan has reached a $465 million settlement with the Justice Department to resolve the issue of Medicaid overpayments for the auto-injection epinephrine pens branded as EpiPen.
“The terms of the settlement do not provide for any finding of wrongdoing on the part of Mylan Inc. or any of its affiliated entities or personnel,” the company said in a statement.
The settlement comes on the heels of last week’s announcement by the Centers for Medicare & Medicaid